xmt-1001

XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized DNA topoisomerase I inhibitor with potent anti-tumor activity. In this formulation, CPT is chemically tethered to a hydrophilic, biodegradable polyacetal polymer known as poly(1-hydroxymethylethylene hydroxymethylformal) or Fleximer. The drug utilizes a novel dual-release mechanism to liberate a camptothecin prodrug, which is then converted within cells into active CPT. This design extends plasma half-life and increases tumor tissue concentrations while potentially reducing common toxicities associated with free CPT and related drugs like irinotecan. Preclinical studies demonstrated improved efficacy and tolerability compared to both CPT and irinotecan in human tumor xenograft models. XMT-1001 has been evaluated in Phase 1 clinical trials for advanced solid tumors, showing favorable pharmacokinetics, safety profile, and evidence of prolonged stable disease in some patients[1][2][3][5][6][8].

Other names

polymeric camptothecin prodrug XMT-1001Fleximer-camptothecin conjugate